OnKure Therapeutics Inc Dossier - Source-backed chat

OnKure Therapeutics Inc

OKURNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.50

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $2.54Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $102.6M

Enterprise Value −$63.9M

Shares Outstanding 40.5M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

OnKure Therapeutics represents a highly compelling, de-risked opportunity in the precision oncology and rare disease space. Following its reverse merger with Reneo Pharmaceuticals in late 2024, the company executed a transformational $150 million private placement in March 2026 led by Access Biotechnology. This financing boosted its cash reserves to $192.1 million, extending its operational runway into 2029. Strategically, OnKure has pivoted from its legacy single-agent asset OKI-219 to focus on its next-generation PI3Kα pan-mutant selective inhibitors: OKI-345 (for breast cancer) and OKI-355 (for vascular anomalies). By sparing wild-type PI3Kα, these candidates aim to avoid the severe on-target toxicities (such as hyperglycemia) that limit current commercial therapies like alpelisib. With IND filings planned for both lead programs in 1H 2027 and mature clinical data from the PIKture-01 trial expected by late 2026, OnKure is well-positioned to achieve major valuation inflection points over the next 12 to 18 months.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$11.00

Mean target$15.50

High · most bullish analyst$21.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$11.0015%

In the bear case, mature data from the PIKture-01 trial of OKI-219 reveals unexpected safety concerns or insufficient clinical efficacy, casting doubt on the translational viability of OnKure's structure-based drug design platform. Preclinical development of OKI-345 and OKI-355 encounters unexpected toxicities or manufacturing delays, pushing the planned IND filings past the 1H 2027 target. The lack of clinical progress accelerates cash burn, forcing the company to seek dilutive financing earlier than expected, depressing the share price toward its cash floor.

Base CaseCentral scenario

$21.0060%

In the base case, OnKure successfully advances OKI-345 and OKI-355 through IND-enabling studies, on track for IND submissions in the first half of 2027. The mature data from the PIKture-01 trial of OKI-219, scheduled for release by late 2026, meets safety and tolerability expectations, confirming the wild-type-sparing thesis of OnKure's design platform. The company's $192.1 million cash balance provides a comfortable runway into 2029, insulating the stock from near-term financing pressures and allowing orderly clinical entry for its next-generation pipeline.

Bull CaseUpside scenario

$30.0025%

In the bull case, OnKure's next-generation pan-mutant selective inhibitors, OKI-345 and OKI-355, demonstrate superior preclinical safety and efficacy profiles, leading to rapid IND clearances in early 2027. Mature data from the PIKture-01 trial of OKI-219 (expected by late 2026) fully validates the company's structure-based chemistry platform, proving that its molecules achieve robust target coverage while sparing wild-type PI3Kα. This clinical validation attracts a major pharmaceutical partnership, providing non-dilutive upfront capital and validating the platform's multi-billion dollar commercial potential in breast cancer and rare vascular anomalies.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Transformational balance sheet strength with $192.1 million in cash as of March 31, 2026, providing an operational runway into 2029.
Strong institutional backing from premier biotech investors, including Access Biotechnology, BVF Partners, and RA Capital.
Differentiated wild-type-sparing PI3Kα platform designed to avoid class-limiting toxicities like hyperglycemia and diarrhea.
Dual-track pipeline targeting both high-value oncology markets (breast cancer via OKI-345) and underserved rare diseases (vascular anomalies via OKI-355).
Near-term platform validation with mature clinical data from the PIKture-01 trial expected by the end of 2026.

Key Investment Risks

Early-stage pipeline risk, with lead assets OKI-345 and OKI-355 still in preclinical development and not expected to enter clinical trials until 2027.
Platform translation risk, as preclinical selectivity may not fully translate to human clinical safety and efficacy.
Intense competition in the PI3Kα space from established players and well-funded biotechs, including Eli Lilly (via its acquisition of Scorpion Therapeutics) and Relay Therapeutics.
High dependence on third-party contract research and manufacturing organizations to advance preclinical and clinical programs.

Thesis Invalidation Triggers

Failure of mature PIKture-01 clinical data to demonstrate a competitive safety or efficacy profile by late 2026.
Delays in submitting IND applications for OKI-345 or OKI-355 beyond the first half of 2027.
Unexpected preclinical toxicities in IND-enabling studies for OKI-345 or OKI-355.
Significant acceleration in quarterly cash burn that shortens the projected runway to 2029.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.